Humana (NYSE:HUM) Given New $290.00 Price Target at Truist Financial

Humana (NYSE:HUM) had its price target boosted by equities research analysts at Truist Financial from $260.00 to $290.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “hold” rating on the insurance provider’s stock. Truist Financial’s price objective would suggest a potential upside of 10.49% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on HUM. Deutsche Bank Aktiengesellschaft reduced their target price on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Wells Fargo & Company cut their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Royal Bank of Canada decreased their price target on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Oppenheimer cut their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $302.00.

Humana Stock Up 3.9 %

Shares of NYSE HUM opened at $262.47 on Monday. Humana has a 12-month low of $213.31 and a 12-month high of $471.37. The firm’s 50-day simple moving average is $272.60 and its 200 day simple moving average is $313.45. The company has a market cap of $31.60 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. On average, research analysts expect that Humana will post 16.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

Institutional investors have recently added to or reduced their stakes in the business. Moors & Cabot Inc. lifted its holdings in shares of Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares during the period. OLD National Bancorp IN lifted its holdings in Humana by 1.8% during the 3rd quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after buying an additional 45 shares during the period. Your Advocates Ltd. LLP lifted its holdings in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. Brooklyn Investment Group grew its position in shares of Humana by 6.7% in the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after buying an additional 46 shares during the last quarter. Finally, Demars Financial Group LLC increased its stake in shares of Humana by 2.7% in the third quarter. Demars Financial Group LLC now owns 1,950 shares of the insurance provider’s stock valued at $618,000 after buying an additional 52 shares during the period. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.